Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02888743 · ClinicalTrials.gov registry record · Phase 2
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
A Phase 2 study of Metastatic Lung Non-Small Cell Carcinoma and Metastatic Colorectal Carcinoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 20
- Study locations
NCT02888743 is a Phase 2 study of Metastatic Lung Non-Small Cell Carcinoma and Metastatic Colorectal Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 110 participants, above the 75-participant average among 39 other Metastatic Lung Non-Small Cell Carcinoma trials with a reported enrollment target (47% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT02888743, a Phase 2 study of Metastatic Lung Non-Small Cell Carcinoma and Metastatic Colorectal Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II trial studies the side effects of durvalumab and tremelimumab and to see how well they work with or without high or low-dose radiation therapy in treating patients with colorectal or non-small cell lung cancer that has spread to other parts of the body (metastatic). Immunotherapy with durvalumab and tremelimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving durvalumab and tremelimumab with radiation therapy may work better in treating patients with colorectal or non-small cell lung cancer.
Conditions Studied
Interventions
- BIOLOGICAL Durvalumab
- RADIATION Radiation Therapy
- BIOLOGICAL Tremelimumab
Study Locations (20)
Connecticut
- Smilow Cancer Hospital Care Center - Guilford - Guilford
- Smilow Cancer Hospital Care Center at Saint Francis - Hartford
- Smilow Cancer Center/Yale-New Haven Hospital - New Haven
- Yale University - New Haven
- Yale-New Haven Hospital North Haven Medical Center - North Haven
- Smilow Cancer Hospital Care Center-Trumbull - Trumbull
- Smilow Cancer Hospital Care Center - Waterford - Waterford
California
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- University of California Davis Comprehensive Cancer Center - Sacramento
Georgia
- Emory University Hospital Midtown - Atlanta
- Emory University Hospital/Winship Cancer Institute - Atlanta
- Emory Saint Joseph's Hospital - Atlanta
Arizona
- Mayo Clinic Hospital in Arizona - Phoenix
- Mayo Clinic in Arizona - Scottsdale
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Brigham and Women's Hospital - Boston
Florida
- Mayo Clinic in Florida - Jacksonville
Kentucky
- University of Kentucky/Markey Cancer Center - Lexington
Maryland
- University of Maryland/Greenebaum Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2017-08-14 |
| Est. Completion | 2027-01-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02888743
The ClinicalTrials.gov registry entry for NCT02888743 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 75-participant average among 39 other Metastatic Lung Non-Small Cell Carcinoma trials with a reported enrollment target (47% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Metastatic Lung Non-Small Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Durvalumab is the first listed.
NCT02888743 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Connecticut, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT02888743 about?
NCT02888743 is a clinical study titled "Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer". This randomized phase II trial studies the side effects of durvalumab and tremelimumab and to see how well they work with or without high or low-dose radiation therapy in treating patients with colorectal or non-small cell lung cancer that has spread to other parts of the body (metastatic). Immunoth...
What is the current status of trial NCT02888743?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2017-08-14. Estimated completion is 2027-01-02.
What conditions does trial NCT02888743 study?
This clinical trial studies the following conditions: Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7.
What interventions are being tested in trial NCT02888743?
The interventions under investigation include: Durvalumab (BIOLOGICAL), Radiation Therapy (RADIATION), Tremelimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02888743?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02888743 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Lung Non-Small Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
RECRUITING · Phase 2
-
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Metastatic Lung Non-Small Cell Carcinoma
All registered trials for this condition
Metastatic Colorectal Carcinoma
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.